Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
10.10
-1.35 (-11.79%)
Mar 31, 2025, 1:15 PM EDT - Market open
Dyne Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Dyne Therapeutics stock have an average target of 47.73, with a low estimate of 17 and a high estimate of 66. The average target predicts an increase of 372.57% from the current stock price of 10.10.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Dyne Therapeutics stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
---|---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 4 | 4 | 4 |
Buy | 3 | 4 | 5 | 5 | 5 | 7 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 9 | 10 | 11 | 10 | 10 | 12 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JP Morgan | JP Morgan | Hold Maintains $18 → $17 | Hold | Maintains | $18 → $17 | +68.32% | Mar 21, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +355.45% | Mar 17, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Maintains $50 | Strong Buy | Maintains | $50 | +395.05% | Mar 17, 2025 |
BMO Capital | BMO Capital | Buy Initiates $50 | Buy | Initiates | $50 | +395.05% | Mar 12, 2025 |
Scotiabank | Scotiabank | Buy Initiates $50 | Buy | Initiates | $50 | +395.05% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 773.77M
Revenue Next Year
n/a
EPS This Year
-3.66
from -3.37
EPS Next Year
-3.86
from -3.66
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 9.6M | 208.7M | ||
Avg | n/a | 1.2M | 134.5M | ||
Low | n/a | n/a | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 17,988.4% | ||
Avg | - | - | 11,556.0% | ||
Low | - | - | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -2.92 | -3.26 | -2.24 | ||
Avg | -3.66 | -3.86 | -2.97 | ||
Low | -4.28 | -4.75 | -4.81 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.